Biohaven Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
274
- Stock Symbol
-
BHVN
- Investments
-
9
- Share Price
-
$12.39
- (As of Friday Closing)
Biohaven General Information
Description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Contact Information
Website
www.biohaven.comCorporate Office
- 215 Church Street
- New Haven, CT 06510
- United States
Corporate Office
- 215 Church Street
- New Haven, CT 06510
- United States
Biohaven Stock Performance
As of 20-Nov-2026, Biohaven’s stock price is $12.39. Its current market cap is $1.87B with 151M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.39 | $13.65 | $8.03 - $18.24 | $1.87B | 151M | 3.22M | -$3.86 |
Biohaven Financials Summary
As of 30-Sep-2026, Biohaven has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,045,603 | 1,552,012 | 3,427,088 | 3,224,971 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (532,305) | (727,458) | (837,832) | (402,639) |
| Net Income | (542,677) | (738,822) | (846,422) | (408,168) |
| Total Assets | 263,676 | 451,447 | 615,107 | 513,212 |
| Total Debt | 300,444 | 284,614 | 36,584 | 30,877 |
Biohaven Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biohaven Comparisons
Industry
Financing
Details
Biohaven Competitors (30)
One of Biohaven’s 30 competitors is Neurogene, a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Neurogene | Formerly VC-backed | New York, NY | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| Design Therapeutics | Formerly VC-backed | Carlsbad, CA | ||||
| CuraSen | Venture Capital-Backed | San Carlos, CA | ||||
| Denali Therapeutics | Formerly VC-backed | South San Francisco, CA |
Biohaven Patents
Biohaven Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260224727-A1 | Compounds and methods for treating, ameliorating, or preventing arthritis | Pending | 31-Jan-2023 | ||
| WO-2022251752-A2 | Dual treatment of migraine | Inactive | 25-May-2021 | ||
| WO-2022251752-A3 | Dual treatment of migraine | Inactive | 25-May-2021 | ||
| WO-2022165291-A1 | Pharmaceutical compositions of cgrp inhibitors and methods of their use | Inactive | 01-Feb-2021 | ||
| WO-2022132989-A1 | Compositions for improved delivery of cgrp inhibitors | Inactive | 17-Dec-2020 | C07K14/57527 |
Biohaven Signals
Biohaven Investments & Acquisitions (9)
Biohaven’s most recent deal was a Merger/Acquisition with Pyramid Biosciences for . The deal was made on 07-Jan-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pyramid Biosciences | 07-Jan-2024 | Merger/Acquisition | Drug Discovery | ||
| PIPr Therapeutics | 10-Mar-2023 | Later Stage VC | Drug Discovery | ||
| Channel Biosciences | 01-Apr-2022 | Merger/Acquisition | Diagnostic Equipment | ||
| Knopp Biosciences | 01-Apr-2022 | Merger/Acquisition | Drug Discovery | ||
| Kleo Pharmaceuticals | 04-Jan-2021 | Merger/Acquisition | Drug Discovery |
Biohaven ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.99 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Biohaven FAQs
-
When was Biohaven founded?
Biohaven was founded in 2013.
-
Where is Biohaven headquartered?
Biohaven is headquartered in New Haven, CT.
-
What is the size of Biohaven?
Biohaven has 274 total employees.
-
What industry is Biohaven in?
Biohaven’s primary industry is Drug Discovery.
-
Is Biohaven a private or public company?
Biohaven is a Public company.
-
What is Biohaven’s stock symbol?
The ticker symbol for Biohaven is BHVN.
-
What is the current stock price of Biohaven?
As of 20-Nov-2026 the stock price of Biohaven is $12.39.
-
What is the current market cap of Biohaven?
The current market capitalization of Biohaven is $1.87B.
-
Who are Biohaven’s competitors?
Neurogene, Alector, Design Therapeutics, CuraSen, and Denali Therapeutics are some of the 30 competitors of Biohaven.
-
What is Biohaven’s annual earnings per share (EPS)?
Biohaven’s EPS for 12 months was -$3.86.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process